X

Trial Profile

Early Access Program of Ampligen® (rintatolimod) in advanced and metastatic pancreatic cancer patients pre-treated with FOLFIRINOX

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rintatolimod (Primary)
Indications Pancreatic cancer
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

20 Jul 2022 Results published in the AIM ImmunoTech Media Release.
16 Mar 2022 According to an AIM ImmunoTech media release, this Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
15 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com